Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases

Abstract

This study shows that low-dose paclitaxel proved to be effective and well tolerated in patients with aggressive refractory cKS, controlling the aggressiveness of the disease. The treatment can be repeated with good response.